These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 31008694)

  • 1. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
    Doernberg M; Krawczyk N; Agus D; Fingerhood M
    Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
    Lofwall MR; Walsh SL
    J Addict Med; 2014; 8(5):315-26. PubMed ID: 25221984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid Use Disorder and Pregnancy.
    O'Donnell FT; Jackson DL
    Mo Med; 2017; 114(3):181-186. PubMed ID: 30228577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients With Opioid Use Disorder Deserve Trained Providers.
    Weimer MB; Tetrault JM; Fiellin DA
    Ann Intern Med; 2019 Dec; 171(12):931-932. PubMed ID: 31766053
    [No Abstract]   [Full Text] [Related]  

  • 6. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steps physicians report taking to reduce diversion of buprenorphine.
    Yang A; Arfken CL; Johanson CE
    Am J Addict; 2013; 22(3):184-7. PubMed ID: 23617857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine diversion and misuse in outpatient practice.
    Lofwall MR; Martin J; Tierney M; Fatséas M; Auriacombe M; Lintzeris N
    J Addict Med; 2014; 8(5):327-32. PubMed ID: 25221985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. America's Opioid Epidemic: Supply and Demand Considerations.
    Clark DJ; Schumacher MA
    Anesth Analg; 2017 Nov; 125(5):1667-1674. PubMed ID: 29049112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethics, Public Health, and Addressing the Opioid Crisis.
    Smith HJ
    AMA J Ethics; 2020 Aug; 22(8):E647-650. PubMed ID: 32880350
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing surveillance of methadone and buprenorphine in the United States.
    Dasgupta N; Bailey EJ; Cicero T; Inciardi J; Parrino M; Rosenblum A; Dart RC
    Pain Med; 2010 Jul; 11(7):1078-91. PubMed ID: 20545875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of buprenorphine research in the opioid crisis.
    Pendergrass SA; Crist RC; Jones LK; Hoch JR; Berrettini WH
    Mol Psychiatry; 2019 May; 24(5):626-632. PubMed ID: 30617273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid misuse epidemic: Addressing opioid prescribing and organization initiatives for holistic, safe and compassionate care.
    Naegle M; ; Mitchell AM; ; Flinter M; ; Dunphy L; ; Vanhook P; ; Delaney KR;
    Nurs Outlook; 2017; 65(4):477-479. PubMed ID: 28821312
    [No Abstract]   [Full Text] [Related]  

  • 16. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
    Andraka-Christou B
    Health Aff (Millwood); 2021 Jun; 40(6):920-927. PubMed ID: 34097509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.
    Leece P; Khorasheh T; Corace K; Strike C; Bayoumi AM; Taha S; Marks E; Pach B; Ahamad K; Grennell E; Holowaty M; Manson H; Straus SE
    BMJ Open; 2019 Dec; 9(12):e032285. PubMed ID: 31843837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma.
    Allen B; Harocopos A
    J Subst Abuse Treat; 2016 Nov; 70():81-86. PubMed ID: 27692193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and misuse of buprenorphine in the management of opioid addiction.
    Cicero TJ; Surratt HL; Inciardi J
    J Opioid Manag; 2007; 3(6):302-8. PubMed ID: 18290581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.